A Phase 1 trial (NCT05451212) is investigating the safety and toxicity of different dosing regimens of an investigational cell therapy called MuSK-CAAR T, which can be given to patients with active, anti-MUSK antibody-positive MG. The gene discussed is MUSK; the disease is myasthenia gravis.